ConductScience.org, home

Paper39384609

Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.

Sidana S and 20 others. Blood Cancer J, 2024. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma. Papers, record 39384609. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39384609

Download JSON
Disease
plasma cell myeloma553 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.
PubMed
Journal
Blood Cancer J
PubMed
Year
2024
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.88, provisional
iCite
Revised in PubMed
2026-11-02
PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sidana SSurbhihttps://orcid.org/0000-0003-3288-7614
2Bankova AKAndriyana K
3Hosoya HHitomi
4Kumar SKShaji Khttps://orcid.org/0000-0001-5392-9284
5Holmes THTyson H
6Tamaresis JJohnhttps://orcid.org/0000-0002-9868-2366
7Le AAnne
8Muffly LSLori Shttps://orcid.org/0000-0002-9887-6136
9Maysel-Auslender SSofia
10Johnston LLaura
11Arai SSally
12Lowsky RRobert
13Meyer EEverett
14Rezvani AAndrew
15Weng WKWen-Kai
16Frank MJMatthew J
17Shiraz PParveen
18Maecker HTHolden T
19Lu YYinghttps://orcid.org/0000-0002-7698-8962
20Miklos DBDavid Bhttps://orcid.org/0000-0003-0717-4305

Source PubMed

See all 21 authorsDownload CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BenzylaminesMajor topic
CyclamsMajor topic
Hematopoietic Stem Cell MobilizationMajor topic
Heterocyclic CompoundsMajor topic
Multiple MyelomaMajor topic
Receptors, Interleukin-8BMajor topic
Adult
Aged
Female
Humans
Male
Middle Aged
Hematopoietic Stem Cell Transplantation

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
KL2TR003143NIHNIH RePORTER
S10RR027582NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04552743MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple MyelomaDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115042106The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma.Leukemia2004https://conductscience.org/library/papers/15042106PubMed
230160591Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study.Leuk Lymphoma2019https://conductscience.org/library/papers/30160591PubMed
319363221Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.Blood2009https://conductscience.org/library/papers/19363221PubMed
410725737Identification of unique truncated KC/GRO beta chemokines with potent hematopoietic and anti-infective activities.J Immunol2000https://conductscience.org/library/papers/10725737PubMed
521131166Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI).J Pain Symptom Manage2011https://conductscience.org/library/papers/21131166PubMed
633915323Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era.Transplant Cell Ther2021https://conductscience.org/library/papers/33915323PubMed
715160937CD34+ CD90+ cells and late hematopoietic reconstitution after autologous peripheral blood stem cell transplantation.Leuk Lymphoma2004https://conductscience.org/library/papers/15160937PubMed
821042307Outcome, toxicity profile and cost analysis of autologous stem cell mobilization.Bone Marrow Transplant2011https://conductscience.org/library/papers/21042307PubMed
929093179A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates.Sci Transl Med2017https://conductscience.org/library/papers/29093179PubMed
1017581613Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.Leukemia2007https://conductscience.org/library/papers/17581613PubMed
1124141007Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.Biol Blood Marrow Transplant2014https://conductscience.org/library/papers/24141007PubMed
1224185588Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Bone Marrow Transplant2014https://conductscience.org/library/papers/24185588PubMed
1330742126Proliferation tracing with single-cell mass cytometry optimizes generation of stem cell memory-like T cells.Nat Biotechnol2019https://conductscience.org/library/papers/30742126PubMed
1432442725Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.Biol Blood Marrow Transplant2020https://conductscience.org/library/papers/32442725PubMed
1518158968Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.Biol Blood Marrow Transplant2008https://conductscience.org/library/papers/18158968PubMed
167595706Factors that influence collection and engraftment of autologous peripheral-blood stem cells.J Clin Oncol1995https://conductscience.org/library/papers/7595706PubMed
1731502160High-Parameter Immune Profiling with CyTOF.Methods Mol Biol2020https://conductscience.org/library/papers/31502160PubMed
1817324341AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma.Clin Lymphoma Myeloma2007https://conductscience.org/library/papers/17324341PubMed
1932010993Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.Am J Hematol2020https://conductscience.org/library/papers/32010993PubMed
2037708911
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Lancet Haematol2023https://conductscience.org/library/papers/37708911PubMed

See all 39 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
41954299CXCL12/CXCR4 axis in neuropathic pain: Insights from preclinical models and translational implications.Mol Pain2026https://conductscience.org/library/papers/41954299PubMed
41688740Metabolic crosstalk among cancer-associated fibroblasts, adipocytes and immune cells as an immunosuppressive tumor microenvironment driver.Exp Mol Med2026https://conductscience.org/library/papers/41688740PubMed
40932993GroβT rapidly and reliably mobilizes primitive hematopoietic stem and progenitor cells in nonhuman primates.Mol Ther Methods Clin Dev2025https://conductscience.org/library/papers/40932993PubMed
40656546Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets.MedComm (2020)2025https://conductscience.org/library/papers/40656546PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD34947PubTator's text mininghttps://conductscience.org/library/genes/947NCBI Gene
CD38952PubTator's text mininghttps://conductscience.org/library/genes/952NCBI Gene
CXCR23579PubTator's text mininghttps://conductscience.org/library/genes/3579NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
PLERIXAFORCHEMBL18442Derived from the trial1https://conductscience.org/library/drugs/CHEMBL18442

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39384609

GET https://conductscience.org/api/papers/v1/39384609/authors?page=2